Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Pregnancy outcomes favourable for women with idiopathic noncirrhotic portal hypertension

25 Nov 2018
The study reaffirms that low-dose aspirin can be considered as a prophylactic of preterm delivery for women at high risk of preeclampsia

Despite condition-related complications, pregnancy in women with idiopathic noncirrhotic portal hypertension (INCPH) results in favourable foetal outcomes in a majority of cases reaching 20 weeks of gestation, reports a new study.

Researchers retrospectively reviewed the medical charts of 16 women with INCPH who had 1 pregnancy during the follow-up period for their liver disease. A total of 24 pregnancies were reported within a median of 24 months after INCPH diagnosis. All patients had serum bilirubin levels <2 mg/dL, and 75 percent had oesophageal varices upon diagnosis.

Over the median gestation duration of 35 weeks, one ectopic pregnancy, four miscarriages and one terminated pregnancy for medical reasons were reported. Eighteen pregnancies reached 20 weeks of gestation, of which one was born very preterm at 27 weeks. Eight were moderately preterm, while nine were term deliveries.

Two infant deaths were reported, one due to infectious meningitis and one due to unknown causes. Another infant had bradycardia during labour but was without sequelae, while another was born small for gestational age. All the other infants were born healthy and with appropriate birthweight.

Six portal hypertension-related complications were documented, including one case of worsening portopulmonary hypertension, three cases of worsening ascites and two cases of variceal bleedings.

No other liver-related complications were reported in the remaining 18 pregnancies. None of the participants developed liver failure or encephalopathy. All patients were asymptomatic at a median follow-up of 27 months after last delivery, and no maternal deaths occurred.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.